Julia A Grigorieva

US Patent:

7858389, Dec 28, 2010

Filed:

Jan 20, 2009

Appl. No.:

12/321392

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Steamboat Springs CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 6, 435 699, 435372, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer (NSCLC) patient is likely to benefit from a monoclonal antibody drug targeting an epidermal growth factor receptor pathway. A mass spectrum is obtained from a sample (e. g. blood sample) from the patient. One or more predefined pre-processing steps are performed on the mass spectrum. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained after the pre-processing steps have been performed. Such values are used in a classification algorithm using a training set comprising class-labeled spectra produced from samples from other patients to identify the patient as being likely to benefit from treatment with the drug.

US Patent:

7858390, Dec 28, 2010

Filed:

Jan 20, 2009

Appl. No.:

12/321394

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Steamboat Springs CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 6, 435 699, 435372, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a colorectal cancer (CRC) patient is likely to benefit from a drug targeting an epidermal growth factor receptor pathway, such as monoclonal antibody EGFR inhibitors.

US Patent:

7867775, Jan 11, 2011

Filed:

Jan 20, 2009

Appl. No.:

12/321393

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Steamboat Springs CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 6, 435 699, 435372, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a head and neck squamous cell carcinoma (HNSCC) patient is likely to benefit from a drug targeting an epidermal growth factor receptor pathway, including small molecule epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and monoclonal antibody EGFR inhibitors.

US Patent:

7879620, Feb 1, 2011

Filed:

Mar 10, 2010

Appl. No.:

12/661129

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Steamboat Springs CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 6, 435 699, 435372, 702 20, 702179

Abstract:

A process of determining whether a patient with a disease or disorder will be responsive to a drug, used to treat the disease or disorder, including obtaining a test spectrum produced by a mass spectrometer from a serum produced from the patient. The test spectrum may be processed to determine a relation to a group of class labeled spectra produced from respective serum from other patients having the or similar clinical stage same disease or disorder and known to have responded or not responded to the drug. Based on the relation of the test spectrum to the group of class labeled spectra, a determination may be made as to whether the patient will be responsive to the drug.

US Patent:

7906342, Mar 15, 2011

Filed:

Sep 8, 2009

Appl. No.:

12/584594

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Steamboat Springs CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 6, 435 699, 435372, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.

US Patent:

8097469, Jan 17, 2012

Filed:

Mar 10, 2010

Appl. No.:

12/661124

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Broomfield CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 699, 435372

Abstract:

A process of determining whether a patient with a disease or disorder will be responsive to a drug, used to treat the disease or disorder, including obtaining a test spectrum produced by a mass spectrometer from a serum produced from the patient. The test spectrum may be processed to determine a relation to a group of class labeled spectra produced from respective serum from other patients having the or similar clinical stage same disease or disorder and known to have responded or not responded to the drug. Based on the relation of the test spectrum to the group of class labeled spectra, a determination may be made as to whether the patient will be responsive to the drug.

US Patent:

8119417, Feb 21, 2012

Filed:

Jan 27, 2011

Appl. No.:

12/931322

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Broomfield CO

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435372, 435 699, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.

US Patent:

8119418, Feb 21, 2012

Filed:

Jan 27, 2011

Appl. No.:

12/931324

Inventors:

Heinrich Röder - Steamboat Springs CO, US
Maxim Tsypin - Steamboat Springs CO, US
Julia Grigorieva - Steamboat Springs CO, US

Assignee:

Biodesix, Inc. - Broomfield CA

International Classification:

G01N 24/00

US Classification:

436173, 436 86, 436171, 435 699, 435372, 702 20, 702179

Abstract:

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.